Ambeed.cn

首页 / / / JAK / JAK2-IN-6

JAK2-IN-6 {[allProObj[0].p_purity_real_show]}

货号:A1364451 Ambeed 开学季,买赠积分,赢豪礼

JAK2-IN-6 是一种有效的选择性 JAK2 抑制剂,IC50 为 22.86 μg/mL。它对 JAK1JAK3 无活性,但对癌细胞具有抗增殖作用。

JAK2-IN-6 化学结构 CAS号:353512-04-6
JAK2-IN-6 化学结构
CAS号:353512-04-6
JAK2-IN-6 3D分子结构
CAS号:353512-04-6
JAK2-IN-6 化学结构 CAS号:353512-04-6
JAK2-IN-6 3D分子结构 CAS号:353512-04-6
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

JAK2-IN-6 纯度/质量文件 产品仅供科研

货号:A1364451 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 JAK1 JAK2 JAK3 Tyk2 其他靶点 纯度
Decernotinib +++

JAK1, IC50: 11 nM

JAK1, Ki: 11 nM

+++

JAK2, Ki: 13 nM

++++

JAK3, Ki: 2.5 nM

+++

TYK2, Ki: 13 nM

{[allProObj[0].p_purity_real_show]}
ZM39923 HCl +

JAK1, pIC50: 4.4

+

JAK3, pIC50: 7.1

EGFR {[allProObj[0].p_purity_real_show]}
Cerdulatinib +++

JAK1, IC50: 12 nM

+++

JAK2, IC50: 6 nM

+++

JAK3, IC50: 8 nM

++++

TYK2, IC50: 0.5 nM

{[allProObj[0].p_purity_real_show]}
Momelotinib +++

JAK1, IC50: 11 nM

++

JAK2, IC50: 18 nM

+

JAK3, IC50: 155 nM

{[allProObj[0].p_purity_real_show]}
XL019 +

JAK1, IC50: 134.3 nM

++++

JAK2, IC50: 2.2 nM

+

JAK3, IC50: 214.2 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Ruxolitinib +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

{[allProObj[0].p_purity_real_show]}
Tofacitinib +

JAK1, IC50: 112 nM

++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
Ruxolitinib (S enantiomer) +++

JAK1, IC50: 3.3 nM

++++

JAK2, IC50: 2.8 nM

++

TYK2, IC50: 19 nM

{[allProObj[0].p_purity_real_show]}
Filgotinib +++

JAK1, IC50: 10 nM

++

JAK2, IC50: 28 nM

+

JAK3, IC50: 810 nM

+

TYK2, IC50: 116 nM

{[allProObj[0].p_purity_real_show]}
Baricitinib +++

JAK1, IC50: 5.9 nM

+++

JAK2, IC50: 5.7 nM

++

TYK2, IC50: 53 nM

{[allProObj[0].p_purity_real_show]}
Gandotinib ++

JAK1, IC50: 19.8 nM

++++

JAK2, IC50: 0.288 nM

JAK2 (V617F), Ki: 0.245 nM

++

JAK3, IC50: 48.0 nM

++

TYK2, IC50: 44 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Oclacitinib maleate +++

JAK1, IC50: 10nM

++

JAK2, IC50: 18nM

+

JAK3, IC50: 99nM

+

TYK2, IC50: 84nM

{[allProObj[0].p_purity_real_show]}
NVP-BSK805 2HCl ++

JAK1, IC50: 31.63 nM

++++

JAK2, IC50: ~0.5 nM

++

JAK3, IC50: 18.68 nM

+++

TYK2, IC50: 10.76 nM

{[allProObj[0].p_purity_real_show]}
Peficitinib {[allProObj[0].p_purity_real_show]}
Go6976 FLT3 {[allProObj[0].p_purity_real_show]}
AZD-1480 ++++

JAK2, IC50: 0.26 nM

{[allProObj[0].p_purity_real_show]}
Fedratinib +++

JAK2, IC50: 3 nM

JAK2 (V617F), IC50: 3 nM

RET,FLT3 {[allProObj[0].p_purity_real_show]}
WP1066 +

JAK2, IC50: 2.3 μM

{[allProObj[0].p_purity_real_show]}
Curcumol {[allProObj[0].p_purity_real_show]}
AZ960 ++++

JAK2, IC50: <3 nM

JAK2, Ki: 0.45 nM

{[allProObj[0].p_purity_real_show]}
GLPG0634 analog {[allProObj[0].p_purity_real_show]}
CEP-33779 ++++

JAK2, IC50: 1.8 nM

{[allProObj[0].p_purity_real_show]}
FLLL32 +

JAK2, IC50: <5 μM

{[allProObj[0].p_purity_real_show]}
WHI-P154 +

JAK3, IC50: 1.8 μM

Src,VEGFR,EGFR {[allProObj[0].p_purity_real_show]}
BMS-911543 ++++

JAK2, IC50: 1.1 nM

+

JAK3, IC50: 75 nM

++

TYK2, IC50: 66 nM

{[allProObj[0].p_purity_real_show]}
TG101209 +++

JAK2, IC50: 6 nM

+

JAK3, IC50: 169 nM

RET,FLT3 {[allProObj[0].p_purity_real_show]}
AT9283 ++++

JAK2, IC50: 1.2 nM

++++

JAK3, IC50: 1.1 nM

{[allProObj[0].p_purity_real_show]}
Pacritinib ++

JAK2, IC50: 23 nM

JAK2 (V617F), IC50: 19 nM

+

JAK3, IC50: 520 nM

++

TYK2, IC50: 50 nM

FLT3 {[allProObj[0].p_purity_real_show]}
Tofacitinib citrate ++

JAK2, IC50: 20 nM

++++

JAK3, IC50: 1 nM

{[allProObj[0].p_purity_real_show]}
FM-381 ++++

JAK3, IC50: 127 pM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

JAK2-IN-6 生物活性

描述 JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective inhibitor of JAK2, exhibiting an IC50 of 22.86 μg/mL. JAK2-IN-6 does not exhibit activity against JAK1 and JAK3. It demonstrates an anti-proliferative effect against cancer cells [1].
体外研究

JAK2-IN-6 (6.3-50 μg/mL; 48 hours) demonstrates notable antiproliferative activity against PC-9, H1975, and PANC-1 cancer cell lines, yielding IC50 values of 18.1 μg/mL, 58.3 μg/mL, and 40.6 μg/mL, respectively [1].

JAK2-IN-6, an intramolecular hydrogen bond forms, maintaining coplanarity between the chlorothiophene substituent and the aminothiazole core. The chlorothiophene moiety resides within the binding pocket adjacent to Val863 and Leu983, extending towards Asp994 of the activation loop and Gly993 of the glycine-rich loop [1].

JAK2-IN-6 参考文献

[1]Ting-Ting Yao, et al. Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors. RSC Adv., 2017, 7, 10353-10360.

JAK2-IN-6 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.98mL

0.60mL

0.30mL

14.89mL

2.98mL

1.49mL

29.78mL

5.96mL

2.98mL

JAK2-IN-6 技术信息

CAS号353512-04-6
分子式C14H10ClN3OS2
分子量 335.832
别名
运输蓝冰
存储条件

粉末 Keep in dark place,Inert atmosphere,2-8°C

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 60 mg/mL(178.66 mM),配合低频超声,并调节pH至5,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。